Analysis confirms benefit of nivolumab combo in teens with advanced Hodgkin lymphoma

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...
The American Journal of Managed Care

Nivolumab With Ipilimumab Approved by FDA for Use in Hepatocellular Carcinoma

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...
The American Journal of Managed Care

Nivolumab Plus Ipilimumab FDA Approved for MSI-H, dMMR Colorectal Cancer

Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression-free ...
ascopubs.org

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials Data ...
The New England Journal of Medicine

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 trial.